ROMIDEPSIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H36N4O6S2
Molecular Weight	540.696
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

SMILES

C\C=C1/NC(=O)[C@H]2CSSCC\C=C\[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@@H](NC1=O)C(C)C

InChI

InChIKey=OHRURASPPZQGQM-GCCNXGTGSA-N

InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C24H36N4O6S2
Molecular Weight	540.696
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description

FR-135313 (also known as Romidepsin reduced) was studied as a selective inhibitor of the human histone deacetylase 1 (HDAC1).

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Histone deacetylase 1 51	Inhibitor 8,504		0.12 nM [IC50]

C_max

Value	Dose	Co-administered	Analyte	Population
377 ng/mL	14 mg/m² 3 times / 4 weeks multiple, intravenous		FR-135313 plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
1549 ng × h/mL	14 mg/m² 3 times / 4 weeks multiple, intravenous		FR-135313 plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
3 h	14 mg/m² 3 times / 4 weeks multiple, intravenous		FR-135313 plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
6%	14 mg/m² 3 times / 4 weeks multiple, intravenous		FR-135313 plasma	Homo sapiens

Sample Use Guides

In Vitro Use Guide

Inhibition of recombinant human HDAC1 after 60 mins by fluorescence assay with IC50 = 0.00012 uM

Substance Class	Chemical
Record UNII	CX3T89XQBK
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

ROMIDEPSIN

Official Name

English

CHROMADAX

Preferred Name

English

FK-228

Code

English

ROMIDEPSIN [MART.]

Common Name

English

(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

Systematic Name

English

Showing 1 to 5 of 21 entries

Previous1 2 3 4 5Next

Show entries

Classification Tree

Code System

Code

Designated/Approved

FDA ORPHAN DRUG

193404

LYMPHOMA

EMA ASSESSMENT REPORTS

ISTODAX (REFUSED: LYMPHOMA, NON-HODGKIN)

Enzyme Inhibitor

NCI_THESAURUS

C1946

Other antineoplastic agents

WHO-ATC

L01XX39

Lymphoma

LIVERTOX

NBK548380

Showing 1 to 5 of 8 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

INN

8656

PRIMARY

MERCK INDEX

m9652

PRIMARY

Merck Index

NSC

630176

PRIMARY

EVMPD

SUB26362

PRIMARY

USAN

SS-77

PRIMARY

Showing 1 to 5 of 22 entries

Previous1 2 3 4 5Next

Show entries

Related Record

Type

Details


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:

[92 to 94] % (average)


					859A956UY8

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

TARGET ORGANISM->INHIBITOR

Amount:


					RV2QAE6UDF

HISTONE DEACETYLASE 2

TARGET -> INHIBITOR

Comments:

Potent HDAC2 inhibitor in a cell-free assay.

Interaction Type:

INHIBITOR

Qualification:

IC50

Amount:

RELATIONSHIP_AMOUNT 47 NANOMOLAR (average)


					O037NFL7YQ

HISTONE DEACETYLASE 1

TARGET -> INHIBITOR

Comments:

Potent HDAC1 inhibitor in a cell-free assay.

Interaction Type:

INHIBITOR

Qualification:

IC50

Amount:

RELATIONSHIP_AMOUNT 36 NANOMOLAR (average)

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Related Record

Type

Details


					4MQ5UQAIB8

FR-135313

METABOLITE ACTIVE -> PRODRUG

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					4MQ5UQAIB8

FR-135313

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

Name	Property Type	Amount
Volume of Distribution	PHARMACOKINETIC	0.63 Liters/Kilogram (average)

Biological Half-life	PHARMACOKINETIC	3 hours (average)

SMILES

InChI

Description<div class="info-popup-container"><div><span class="pop-sub-key ">Sources:&nbsp;</span><span class="pop-sub-val"><span class="ext-link"><a target="_self" href="https://pubmed.ncbi.nlm.nih.gov/26331334">https://pubmed.ncbi.nlm.nih.gov/26331334</a></span></span></div></div>

Approval Year

Targets

Cmax

AUC

T1/2

Funbound

Sample Use Guides

Description

C_max

T_1/2

F_unbound